Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Sintilimab or Combined With Chemotherapy for Stage III Driven Gene Mutation Negative Non-small Cell Lung Cancer

NCT04728724 is registered in ClinicalTrials.gov with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor.

NCT NCT04728724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04728724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Sintilimab or Combined With Chemotherapy for Stage III Driven Gene Mutation Negative Non-small Cell Lung Cancer
Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Phase
Phase 2
Overall status
Recruiting
Start date
September 10, 2022
Completion date
December 31, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer stage iii